Acucela Strikes Third Ophthalmology Deal With Otsuka For Glaucoma Drug
This article was originally published in PharmAsia News
Seattle-based ophthalmology specialist Acucela has struck its third partnership with Japanese pharma Otsuka Pharmaceutical Co., this time to collaborate on development of a preclinical glaucoma treatment
You may also be interested in...
Aiming at expanding beyond its blockbuster schizophrenia drug and widely popular personal care products, Japan's fifth-largest drug maker Otsuka Pharmaceutical is reportedly preparing an initial public offering in Tokyo estimated to be valued at over ¥1 trillion ($12 billion) based on calculations of the stock option exercise price, making Otsuka one of the largest Japanese drug makers to go public in a decade
Despite a crowded marketplace - with at least seven marketed drugs in at least three different classes -glaucoma remains a disease with a huge unmet need
Otsuka Holdings, the parent company of Japan's fifth-largest pharmaceutical company Otsuka Pharmaceutical, could go public on the Tokyo Stock Exchange within the year